Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Conditions

Breast Cancer

Keywords

TRIPLE-NEGATIVE, BREAST CANCER

Brief summary

Triple-negative breast cancer (TNBC) has a relatively bad prognosis whereas there is no standard regimen. Some data showed that platins could improve the efficacy of advance TNBC. In this trial, it is the hypothesis that TP (docetaxel plus carboplatin) has a better efficacy than EC-T (epirubicin plus cyclophosphamide followed by docetaxel).

Yimeng Chen, Xue Wang, Feng Du, Jian Yue, Yiran Si et al. (11 authors)

Cancer Biology and Medicine2023-03-0211 citations

10.20892/j.issn.2095-3941.2022.0525

Abstract 5084: <i>KMT2D</i> and <i>PIK3CA</i> mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer

Xue Wang, Feng Du, Jian Yue, Yiran Si, Lina Cui et al. (9 authors)

Cancer Research2022-06-151 citations

10.1158/1538-7445.am2022-5084

Abstract 5689: Effects of homologous recombination-related gene mutation subtypes on gene instability and the efficacy of platinum-containing regiments in triple-negative breast cancer

Xue Wang, Yimeng Chen, Feng Du, Jian Yue, Yiran Si et al. (11 authors)

Cancer Research2022-06-15

10.1158/1538-7445.am2022-5689

Abstract P1-08-12: The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer

Yimeng Chen, Xue Wang, Feng Du, Jian Yue, Yiran Si et al. (9 authors)

Cancer Research2022-02-15

10.1158/1538-7445.sabcs21-p1-08-12

Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.

Zheng F, Du F, Wang W, Wang Y, Li M, Zhao J, Wang X, Yue J, Wang J, Yang Z, Cai R, Ma F, Fan Y, Li Q, Zhang P, Xu B, Yuan P.

2021-10-1411 citations

10.1007/s10549-021-06401-6

Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.

Fangchao Zheng, Feng Du, Yongsheng Wang, Xue Wang, Jiayu Wang et al. (10 authors)

Journal of Clinical Oncology2021-05-20

10.1200/jco.2021.39.15_suppl.529

Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer.

Peng Yuan, Feng Du, Jiayu Wang, Fei Ma, Ying Fan et al. (6 authors)

Journal of Clinical Oncology2016-05-202 citations

10.1200/jco.2016.34.15_suppl.1068

Interventions

DRUGEC-T

four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)

DRUGTP

six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Healthy volunteers

No

Inclusion criteria

* Triple-negative breast cancer * Older than 18 years old * Have tumor resection surgery * Sufficient organ function (marrow, heart, liver)

Exclusion criteria

* Other malignancy * Other serious disease( marrow, heart, liver)

Design outcomes

Primary

Measure	Time frame	Description
Disease Free Survival (DFS) of 3 years	3 years after mastectomy	local recurrence, distant metastasis, the secondary primary malignancy

Secondary

Measure	Time frame	Description
Safety Profiles	Up to 24 weeks	All adverse events occurring during chemotherapy are to be recorded in the case report form, including hemotologic and nonhemotologic toxicities.

Countries

China

Outcome results

None listed